![Cancers | Free Full-Text | Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide Cancers | Free Full-Text | Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide](https://www.mdpi.com/cancers/cancers-14-02219/article_deploy/html/images/cancers-14-02219-g003.png)
Cancers | Free Full-Text | Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
![Urofrance | Évaluation de l'index Phi pour la prédiction de l'agressivité du cancer de la prostate : étude sur 164 prostatectomies radicales - Urofrance Urofrance | Évaluation de l'index Phi pour la prédiction de l'agressivité du cancer de la prostate : étude sur 164 prostatectomies radicales - Urofrance](https://www.urofrance.org/fileadmin/presentations/data/2013/22112013/S-342A/1415/557/V_VLAEMINCK-GUILLEM/Diapositive12.jpg)
Urofrance | Évaluation de l'index Phi pour la prédiction de l'agressivité du cancer de la prostate : étude sur 164 prostatectomies radicales - Urofrance
![Race-Specific Trends in Prostate Cancer Screening and Presentation before and after the 2012 United States Preventive Services Task Force Statement | Urology Practice Race-Specific Trends in Prostate Cancer Screening and Presentation before and after the 2012 United States Preventive Services Task Force Statement | Urology Practice](https://www.auajournals.org/cms/asset/c7560027-7ce5-4009-b22c-828894a62298/upj.0000000000000274f1.gif)
Race-Specific Trends in Prostate Cancer Screening and Presentation before and after the 2012 United States Preventive Services Task Force Statement | Urology Practice
![ESMO 2022: Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castration-resistant prostate cancer in the VISION trial ESMO 2022: Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castration-resistant prostate cancer in the VISION trial](https://larvolclin.s3.us-west-2.amazonaws.com/resize_166306090938969400863204badaece6.png)
ESMO 2022: Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castration-resistant prostate cancer in the VISION trial
![Do patients with low volume prostate cancer have prostate specific antigen recurrence following radical prostatectomy? | Journal of Clinical Pathology Do patients with low volume prostate cancer have prostate specific antigen recurrence following radical prostatectomy? | Journal of Clinical Pathology](https://jcp.bmj.com/content/jclinpath/61/9/1038/F1.large.jpg)
Do patients with low volume prostate cancer have prostate specific antigen recurrence following radical prostatectomy? | Journal of Clinical Pathology
![PSA antigène prostatique spécifique de l'échantillon de sang avec du tube de prélèvement des tubes de prélèvement et du cathéter Photo Stock - Alamy PSA antigène prostatique spécifique de l'échantillon de sang avec du tube de prélèvement des tubes de prélèvement et du cathéter Photo Stock - Alamy](https://c8.alamy.com/compfr/f4kekr/psa-antigene-prostatique-specifique-de-l-echantillon-de-sang-avec-du-tube-de-prelevement-des-tubes-de-prelevement-et-du-catheter-f4kekr.jpg)
PSA antigène prostatique spécifique de l'échantillon de sang avec du tube de prélèvement des tubes de prélèvement et du cathéter Photo Stock - Alamy
![Tissue PSA distribution across the prostate gland at t = 0.5 y, tumor... | Download Scientific Diagram Tissue PSA distribution across the prostate gland at t = 0.5 y, tumor... | Download Scientific Diagram](https://www.researchgate.net/publication/310585827/figure/fig4/AS:431670072483843@1479929573889/Tissue-PSA-distribution-across-the-prostate-gland-at-t-05-y-tumor-volume-evolution.png)
Tissue PSA distribution across the prostate gland at t = 0.5 y, tumor... | Download Scientific Diagram
![Frontiers | Influence of Tumor Burden on Serum Prostate-Specific Antigen in Prostate Cancer Patients Undergoing Radical Prostatectomy Frontiers | Influence of Tumor Burden on Serum Prostate-Specific Antigen in Prostate Cancer Patients Undergoing Radical Prostatectomy](https://www.frontiersin.org/files/Articles/656444/fonc-11-656444-HTML/image_m/fonc-11-656444-t003.jpg)
Frontiers | Influence of Tumor Burden on Serum Prostate-Specific Antigen in Prostate Cancer Patients Undergoing Radical Prostatectomy
![Author Correction: Pretreatment PSA levels affects the completion rate of Ra-223 treatment | Scientific Reports Author Correction: Pretreatment PSA levels affects the completion rate of Ra-223 treatment | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-021-96170-5/MediaObjects/41598_2021_96170_Fig1_HTML.png)
Author Correction: Pretreatment PSA levels affects the completion rate of Ra-223 treatment | Scientific Reports
![Dm.75.00x2.5x1.95x2.0 piston + 0.60 price for 1 PCs Ford duratorg 1.6 TDCi, PSA dv6c, Volvo d4162t KS Art. 41253610 - AliExpress Dm.75.00x2.5x1.95x2.0 piston + 0.60 price for 1 PCs Ford duratorg 1.6 TDCi, PSA dv6c, Volvo d4162t KS Art. 41253610 - AliExpress](https://ae01.alicdn.com/kf/Sb7f0eaf1a5ac4aac8d1e7d7fc121933cS/Dm-75-00x2-5x1-95x2-0-piston-0-60-price-for-1-PCs-Ford-duratorg-1.jpg_.webp)
Dm.75.00x2.5x1.95x2.0 piston + 0.60 price for 1 PCs Ford duratorg 1.6 TDCi, PSA dv6c, Volvo d4162t KS Art. 41253610 - AliExpress
![Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer | BMC Research Notes | Full Text Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer | BMC Research Notes | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13104-021-05641-5/MediaObjects/13104_2021_5641_Fig1_HTML.png)
Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer | BMC Research Notes | Full Text
![Frontiers | Influence of Tumor Burden on Serum Prostate-Specific Antigen in Prostate Cancer Patients Undergoing Radical Prostatectomy Frontiers | Influence of Tumor Burden on Serum Prostate-Specific Antigen in Prostate Cancer Patients Undergoing Radical Prostatectomy](https://www.frontiersin.org/files/MyHome%20Article%20Library/656444/656444_Thumb_400.jpg)